Table 1.
General characteristics of the studies included in the meta-analysis.
| Author | Country | Cases (LP) | Controls | HPV+ Cases | HPV+ Controls | Types of HPV Tested | Type of LP | HPV+ Cases/LP Type |
|---|---|---|---|---|---|---|---|---|
| Campisi G. et al. (2004) [35] | Italy | 71 | 90 | 14 | 5 | 6, 16, 18, 31, 33 | AE/n-AE | AE HPV+ 9 n-AE HPV+ 5 |
| Farhadi S. et al. (2020) [38] | Iran | 32 | 20 | 8 | 0 | 11, 16, 18, 33–73 | AE/n-AE | AE HPV+ 8 n-AE+ 0 |
| Maitland NJ. et al. (1987) [18] | UK | 8 | 12 | 7 | 5 | 16 | NA | NA |
| Mohhamadi M. et al. (2023) [6] | Iran | 25 | 25 | 14 | 7 | 16, 18 | AE/n-AE | AE HPV+ 8 n-AE HPV+ 6 |
| Nafarzadeh S. et al. (2017) [31] | Iran | 50 | 7 | 30 | 1 | NA | NA | NA |
| Pierangeli A. et al. (2016) [36] | Italy | 12 | 54 | 9 | 19 | 6, 11, 16, 18, 31, 33, 53, 58 | NA | NA |
| Pol CA. et al. (2015) [28] | India | 30 | 30 | 21 | 0 | 16 | n-AE | n-AE HPV+ 21 |
| Razavi SM. et al. (2009) [32] | Iran | 29 | 9 | 14 | 1 | 18 | NA | NA |
| Radochova V. et al. (2015) [33] | Czech Republic | 45 | 24 | 24 | 14 | 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51–56, 58, 59, 61, 62, 64, 66–73, 81–84, IS39, CP6108 | AE/n-AE | AE HPV+ 16 n-AE HPV+ 8 |
| Sameera A. et al. (2015) [30] | India | 15 | 15 | 13 | 0 | 18 | AE/n-AE | AE HPV+ 5 n-AE HPV+ 8 |
| Szarka K. et al. (2009) [34] | Hungary | 119 | 72 | 39 | 3 | 6, 11, 16, 18, 31, 33 | AE/n-AE | AE HPV+ 26 n-AE HPV+ 13 |
| Yildirim B. et al. (2012) [15] | Turkey | 65 | 15 | 14 | 0 | 16 | NA | NA |
| Zendeli-Bedejeti L. et al. (2019) [37] | Macedonia | 40 | 40 | 12 | 1 | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56–59 | NA | NA |
AE: atrophic-erosive; n-AE: non-atrophic-erosive; NA: not applied.